Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
Rifabutin-Associated Uveitis
Moustafa B., Hille K., Ruprecht K. W.
University Eye Hospital, Homburg/Saar
Purpose: Hypopyon-Uveitis has been identified as a side effect in Patients with acquired immunodeficiency syndrome who are treated for Mycobacterium avium complex (MAC) infection with systemic rifabutin. We report a AIDS Patient with unilateral uveitis under therapy with rifabutin and hoch active antiretroviral therapy (HAART).
Method: A 37-year-old, human immunodeficiency virus (HIV)-positive man was initially seen with pain and decreased visual acuity in the right eye. Visual acuity was 0,5p. The right eye showed advanced iridocyclitis with cells in the anterior chamber, keratic precipitates, posterior synechiae and hypopyon (2mm). The posterior segment was unremarkable. He had a medical history of two years of a advanced HIV-Infection in stadium CDC C3. The patient was started on HAART, consisting of Retrovirâ, combivirâ, viramuneâ and combined antimycobacterial therapie with Rifabutin, Klacidâ, Tavanicâ, Cotrim forteâ and Myambutolâ since 2000.
Results: In our case the patient developed an anterior form of uveitis attribute to the toxic effect of Rifabutin. We stopped Rifabutin and begun with a local steroid (prednisolonacetat) and cycloplegia eyedrops. The patient showed a rapid recovery.
Conclusions: Because of lifelong HIV therapy with highly active antiretroviral chemo